Stabilization of thrombocytes at ambient temperatures

• US 10,064,404 B2
• Filed: 06/09/2015
• Issued: 09/04/2018
• Est. Priority Date: 06/10/2014
• Status: Active Grant

• Current Assignee: Biomatrica, Inc. (Exact Sciences Corporation)
• Original Assignee: Biomatrica, Inc. (Exact Sciences Corporation)
• Inventors: Muller, Rolf, Desharnais, Joel, Wilkinson, Steven P., Arendt, Victoria, Diaz, Paul
• Primary Examiner(s): Berke-Schlessel, David W
• Application Number:
  US15/316,677
• Publication Number:
  US 20170196220A1
• Time in Patent Office: 1,183 Days
• Field of Search: None
• CPC Class Codes: A01N 1/021 Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

Claims

1. A composition for substantially stable storage of one or more thrombocytes at ambient temperature, comprising a halogenated disaccharide derivative and an anticoagulant,

wherein the halogenated disaccharide derivative is present at 0.1-50 μ

M, and

wherein the thrombocytes are stabilized for a period of at least 6 hours.

2. The composition of claim 1, wherein the composition further comprises a buffer.

3. The composition of claim 1, wherein the anticoagulant is hirudin.

4. The composition of claim 1, wherein the halogenated disaccharide derivative is selected from the group consisting of sucralose (1,6,-dichloro-1,6,dideoxy-β

-D-fructofuranosyl-4-chloro-4-deoxy-α

-D-galactopyranoside), trichloronated maltose, 1,6,-dichloro-1,6,dideoxy-β

-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α

-D-galactopyranoside, 1,6,-dichloro-1,6,dideoxy-β

-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α

-D-galactopyranoside, and combinations thereof.

5. The composition of claim 1, wherein the composition consists essentially of hirudin and sucralose (1,6,-dichloro-1,6,dideoxy-β

-D-fructofuranosyl-4-chloro-4-deoxy-α

-D-galactopyranoside).

6. The composition of claim 1, wherein the anticoagulant is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate.